Literature DB >> 8842032

Carrier-mediated intestinal transport of drugs.

A Tsuji1, I Tamai.   

Abstract

Recent advances in the field of carrier-mediated intestinal absorption of of amino acids, oligopeptides, monosaccharides, monocarboxylic acids, phosphate, bile acids and several water-soluble vitamins across brush-border and basolateral membranes are summarized. An understanding of the molecular and functional characteristics of the intestinal membrane transporters will be helpful in the utilization of these transporters for the enhanced oral delivery of poorly absorbed drugs. Some successful examples of the synthesis of prodrugs recognized by the targeted transporters are described. Functional expression of the multidrug resistance gene product, P-glycoprotein, as a primary active transporter in the intestinal brush-border membrane leads to net secretion of some drugs such as anticancer agents in the blood-to-luminal direction, serving as a secretory detoxifying mechanism and as a part of the absorption barrier in the intestine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842032     DOI: 10.1023/a:1016086003070

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  101 in total

1.  Hypoglycemic effect of intestinally administered monosaccharide-modified insulin derivatives in rats.

Authors:  M Haga; K Saito; T Shimaya; Y Maezawa; Y Kato; S W Kim
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-07       Impact factor: 1.645

2.  Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs.

Authors:  T Mizuma; K Ohta; M Hayashi; S Awazu
Journal:  Biochem Pharmacol       Date:  1992-05-08       Impact factor: 5.858

Review 3.  Structure and function of P-glycoprotein in normal liver and small intestine.

Authors:  Z C Gatmaitan; I M Arias
Journal:  Adv Pharmacol       Date:  1993

4.  Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2).

Authors:  M Hu; R T Borchardt
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

5.  Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes.

Authors:  K Inui; M Yamamoto; H Saito
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

6.  Functional expression of transporter for beta-lactam antibiotics and dipeptides in Xenopus laevis oocytes injected with messenger RNA from human, rat and rabbit small intestines.

Authors:  I Tamai; N Tomizawa; T Takeuchi; K Nakayama; H Higashida; A Tsuji
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

7.  Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.

Authors:  R Liang; Y J Fei; P D Prasad; S Ramamoorthy; H Han; T L Yang-Feng; M A Hediger; V Ganapathy; F H Leibach
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

8.  Renin inhibitor: transport mechanism in rat small intestinal brush-border membrane vesicles.

Authors:  N Hashimoto; T Fujioka; T Toyoda; N Muranushi; K Hirano
Journal:  Pharm Res       Date:  1994-10       Impact factor: 4.200

Review 9.  Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals.

Authors:  M Bugaut
Journal:  Comp Biochem Physiol B       Date:  1987

10.  pGlu-L-Dopa-Pro: a tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion.

Authors:  J P Bai
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

View more
  49 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 2.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

4.  Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines.

Authors:  Pascale Anderle; Vera Rakhmanova; Katie Woodford; Noa Zerangue; Wolfgang Sadée
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

Review 5.  Theoretical predictions of drug absorption in drug discovery and development.

Authors:  Patric Stenberg; Christel A S Bergström; Kristina Luthman; Per Artursson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

Authors:  Ritesh Jain; Sridhar Duvvuri; Viral Kansara; Nanda Kishore Mandava; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-12-03       Impact factor: 5.875

7.  Computational approaches for modeling human intestinal absorption and permeability.

Authors:  Govindan Subramanian; Douglas B Kitchen
Journal:  J Mol Model       Date:  2006-04-01       Impact factor: 1.810

8.  Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.

Authors:  Banmeet S Anand; Ashim K Mitra
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 9.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

10.  A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.

Authors:  G P Camenisch; W Wang; B Wang; R T Borchardt
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.